BLS vs EYE

ASX Healthcare sector comparison — updated 3 Sep 2026 — Healthcare sector

BLS

BLSPHARMA FPO [BLS]

56MEDIUM

EYE

NOVA EYE FPO [EYE]

58MEDIUM

Score Breakdown

BLS EYE
Technical
91
46
Catalyst
54
54
Sentiment
50
50
Fundamental
100
60
Momentum
86
65
Risk Gate
50
50

Key Metrics

BLS Metric EYE
$249.9MMarket Cap$38.5M
310KAvg Volume (20d)199K
+0.0%Short InterestN/A
$1.20052-Week High$0.205
$0.33052-Week Low$0.100
+0.4%Daily Change+3.8%
$1.110Reference Price$0.135
+66.1%ROE-26.1%
+18.7%Profit Margin-12.4%

Active Signals

BLS Signals

RSI is running hot — overbought territory, so expect some pullback risk
MACD momentum is picking up steam
Trading above both moving averages — the trend is your friend here
Volume surging at 3.4x normal while price climbs — real buying conviction behind this move
RSI is overbought but volume confirms it — this could be genuine momentum, not just froth
On a tear — up 20.7% over the last 5 days
Beating the Small Ords index — relative strength of 1.25, so it's outpacing the pack
Volatility is expanding fast — choppy price action, so buckle up

EYE Signals

Stochastic just turned bullish from a low level — early reversal sign
Lagging the Small Ords index — relative strength of 0.89, underperforming its peers
Below the 200-day average — the long-term trend is still working against it
Critical cash runway (1.2 quarters)
Low P/S ratio (1.1x)
Moderate revenue growth (+11%)
EPS estimates revised upward (+10pts)
Small-cap ($20-100M)

Ask Scout AI to compare BLS and EYE in depth.

Open Scout AI →

Track both stocks and 2,200+ more — Free

Daily AI-powered screening across every ASX small cap.

Open Screener

Related Comparisons

CMP vs RHT →EYE vs IIQ →EYE vs LDX →EYE vs LGP →EYE vs SPL →
BLS Full Analysis → EYE Full Analysis → Healthcare Sector → All Comparisons →
GENERAL INFORMATION ONLY. SmallCapData provides algorithmic screening data and does not constitute personal financial advice, a recommendation, or an offer to buy or sell any security. This content is produced by an algorithm, not a licensed financial adviser. You should consider seeking independent financial advice before making any investment decision. Past performance is not indicative of future results. Trading in small-cap securities carries a high degree of risk, including the risk of total loss of capital. The author may hold positions in mentioned securities. SmallCapData does not hold an Australian Financial Services Licence (AFSL).